Status:
COMPLETED
MEMO-Medical Marijuana and Opioids Study
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Fordham University
Columbia University
Conditions:
Opioid Use
Marijuana
Eligibility:
All Genders
18+ years
Brief Summary
The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.
Detailed Description
The overarching goal of the study is to understand how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and adverse events. The ...
Eligibility Criteria
Inclusion
- At least 18 years of age
- English or Spanish fluency
- New certification for medical cannabis within 90 days
- No medical cannabis use in the 6 months prior to certification
- Medical cannabis qualifying complication of "chronic or severe pain"
- Use of prescribed or illicit opioid analgesics within 30 days
Exclusion
- Inability to provide informed consent
- Inability to complete study visits over 18 months
- Qualifying conditions for medical cannabis in NY that are likely to cause unique pain syndromes (cancer, epilepsy, multiple sclerosis, spinal cord injury, amyotrophic lateral sclerosis, Parkinson's disease, inflammatory bowel disease, Hungtington's disease)
- Terminal illness
- Current or prior psychotic disorder
Key Trial Info
Start Date :
September 4 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 14 2023
Estimated Enrollment :
257 Patients enrolled
Trial Details
Trial ID
NCT03268551
Start Date
September 4 2018
End Date
July 14 2023
Last Update
November 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Health System
The Bronx, New York, United States, 10451
2
Vireo Health
White Plains, New York, United States, 10601